The study of neurotropic autoantibody levels in patients with epilepsy, Parkinson’s disease and schizophrenia

The blood plasma IgG autoantibodies to human protein S-100, to NMDA-receptors and to dopamine receptor type 2 were determined in 13 epilepsy patients with secondary generalized seizures, 16 - in Parkinson patients, 33 - in schizophrenia patients at the age of 18-78. All the enrollees were male. The level of antibodies to S-100 in patients with Parkinson’s was close to normal, it was increased in epilepsy patients and in 59 % of schizophrenia patients. Herewith, in 41 % of schizophrenia patients the levels of autoantibodies to protein S-100 were within normal range. The level of autoantibodies to NMDA-receptors was moderately increased in patients with Parkinson’s and noticeably increased in patients with epilepsy. 45 % of patients with schizophrenia showed a significant increase in NMDA receptor autoantibodies, the others - had normal levels of antibodies. The level of autoantibodies to dopamine receptors in patients with Parkinson’s was normal, and in patients with epilepsy it was significantly increased. In 21 % of patients with schizophrenia the level of autoantibodies to dopamine receptors was normal and in 79 % of patients had significantly increased level of autoantibodies. In patients with schizophrenia high levels of antibodies to dopamine receptors overlapped with high levels of autoantibodies to S-100.

аутоантитела, белок S-100, NMDA-рецепторы, дофаминовые рецепторы, паркинсонизм, эпилепсия, шизофрения, antibodies, protein S-100, NMDA-receptors, dopamine receptors, Parkinsonism, epilepsy, schizophrenia

1. Zaychik ASh, Poletaev AB, Churilov LP. Natural autoantibodies, immunological theories and preventive medicine. Vestnik Sankt-Peterburgskogo universiteta 2013; 2(11): 3–16 (in Russian).

2. Poletaev AB. Physiological Immunology (natural autoantibodies and nanomedicine problems). Moscow: Miklos; 2010 (in Russian).

3. Poletaev AB, Morozov ST, Kovalev IE. Regulatory metasystem. Immune- neuroendocrine regulation of homeostasis. Moscow: Meditsina; 2002 (in Russian).

4. Mamtseva GI, Baturin VA, Nersesyants ZV. Diagnostic value of determining the level of antibody to the myosin with cardiomyopathies. Rossiyskiy allergologicheskiy zhurnal 2012; (1): 195–6 (in Russian).

5. Poletaev AB. Antibodies to the antigens of the nervous tissue and pathology of the nervous system. Vestnik MEDSI 2011; (13): 14–21 (in Russian).

6. Sepiashvili RI, Kimova MV, Kalinina EV, Martynov LA, Kostyushev DS, Shoenfeld Y, Suchkov SV. Antibodies as molecular tools in the diagnosis of multiple sclerosis. Allergologiya i immunologiya 2010; 11(3): 243–9 (in Russian).

7. Globa OV. Biological factors of spasmodic paroxysms in children. Cand. Med. Sci [thesis]. Moscow; 1998 (in Russian).

8. Fedonyuk VP, Pokrovskaya LA, Chepur SV, Varlashova MB. Experimental search and development of drugs intended for the relief of seizures of chemical etiology. In: Proceedings of the Russian scientific conference «Medical aspects of radiation and chemical safety». St. Petersburg; 2001. P. 421–2 (in Russian).

9. Boyko AS, Pozhidaev IV, Cherevko NA, Ivanova SA. Polymorphisms of NMDA-receptor gene in schizophrenic patients with tardive dyskinesia. Fundamentalnye issledovaniya 2015; (1): 231–4 (in Russian).